Novo Nordisk Lifts Guidance as Wegovy Pill Uptake Boosts Investor Confidence

Novo Nordisk shares surged on Wednesday after the Danish pharmaceutical giant raised its full-year outlook, citing robust early demand for its oral weight-loss treatment. The company, which has faced recent pressure over supply constraints and competition in the obesity market, said the pill version of its blockbuster Wegovy franchise is seeing stronger-than-expected adoption since its launch earlier this year. Investors welcomed the update, sending the stock sharply higher and easing concerns about the firm's growth trajectory. The guidance lift signals that Novo's bet on oral semaglutide could expand its reach beyond injectable therapies, potentially capturing a larger slice of the booming weight-management sector. With obesity rates climbing globally and rivals racing to introduce alternatives, the pill's convenience may prove a key differentiator. Novo's ability to scale production and meet demand will be critical in the coming quarters. The market's positive reaction reflects growing confidence that the company can defend its leadership in a fiercely competitive field.